An innovative nano-immune agonist has been developed to significantly enhance immunotherapy ... activates the cGAS-STING signaling pathway, a key player in innate immune activation.

Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy ... the cGAS-STING signaling pathway, a key player in innate immune activation.

Prof. WU Zhengyan from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, in collaboration with ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and ...

Nine Utrecht researchers to receive NWO grants for groundbreaking and high-risk research ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Tumor Model of Colorectal Cancer (CRC),” TP-317 demonstrated potent anti-tumor activity and synergy with checkpoint inhibitors. Key findings include: TP-317 activated STING and IFN-γ pathways ...

They found that a STING agonist can reactivate these pathways in breast cancer cells, but it also does so in normal cells, suggesting that this is not a good way to create a therapeutic window.

Notably, high SMB melanoma tumors deficient in STING expression escaped immune control by reducing infiltration and activation ... cancer cells as a critical factor for tumor immunogenicity and should ...